Urine Fetuin A as a Predictor of Kidney Decline in High Blood Pressure
Observes whether a urine protein predicts kidney decline in adults with high blood pressure.
Key facts
- Who runs it
- University Hospital Ostrava
- Where
- Ostrava, CzechiaSee the site
- Trial code
- Registry title
- Fetuin A as a Predictor of Deterioration of Renal Function in Hypertonic Patients
- Status
- Recruiting
- People taking part
- 200 people, planned
- Started
- 1 Jul 2023
- Expected to end
- 31 Dec 2026
- Type of study
- Observational
- Record updated
- 27 July 2023
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with high blood pressure who take at least one blood pressure medicine. It studies whether a urine marker, Fetuin A, can predict worsening kidney function.
- Age
- 18 to 100 years
- Sex
- All sexes can join.
- Disease stage
- Arterial hypertension (high blood pressure) treated with at least one blood pressure medicine. High blood pressure that is out of control cannot be included.
- Earlier treatment
- Must take at least one blood pressure medicine.
Main reasons for not taking part
- Any type of diabetes
- Uncontrolled high blood pressure (office blood pressure above 180/110 mmHg)
- Kidney replacement treatment
- Rheumatoid disease (for example rheumatoid arthritis or lupus) or positive ANA/ENA screening
- Acute infection (CRP above 50 mg/l)
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Arterial hypertension treated by at least one antihypertensive agent
Who cannot take part
- Patient with renal replacement therapy
- Decompensated arterial hypertension defined as office blood pressure >180/110 mmHg or on Ambulatory Blood Pressure Monitoring (ABPM)
- Present rheumatoid disease (rheumatoid arthritis, systemic lupus, sclerodermia, dermatomyositis, Inflammatory Bowel Disease, etc.), positivity of antinuclear antibody (ANA) / extractable nuclear antigen (ENA) screening
- Acute infection defined as C-Reactive Protein (CRP) >50 mg/l
- Terminal incurable illness
- Diabetes mellitus of any type, defined as fasting glucose >7,0 mmol/l or any glycemia >11,0 mmol/l, or HbA1c>48 mmol/mol
- Severe impairment of liver function defined as cirrhosis, Alanine Transaminase or ASpartate Transferase (ALT or AST) >10 µkat/l
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 100 years old?
Where in Czechia
- University Hospital Ostrava, - Department of Internal Medicine and CardiologyOstrava, CzechiaContact: Jiří HynčicaTaking people
About the trial
What the trial wants to find out
Commonly used parameters (creatinine, estimated glomerular filtration rate, and urine albumin/creatinine ratio) for prediction of decline of renal function are sensitive for advanced kidney impairment. Modified human urine Fetuin A (urine Fetuin A) with specific modification in urine (Fetuin A) can earlier predict the progression of kidney disease in patients with diabetes. Studies evaluating urine Fetuin A in hypertonic patients are still lacking.
The group in the trial
- Patients with hypertension, resistant hypertension, and secondary hypertension
Patients with arterial hypertension, resistant arterial hypertension, and secondary hypertension.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Modified Urine Fetuin A as a Predictor of Deterioration of Renal Function in Patients With Resistant and Non-resistant Hypertension
- Plain-language title
- Urine Fetuin A as a Predictor of Kidney Decline in High Blood PressureGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT05963126, who can take part
- Record updated
- 27 July 2023